Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 1.00 |
| ▸ | CTSB | P07858 | 1/20 | 0.66 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Simeprevir SCHEMBL2229194 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL18539068 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL6876363 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL829744 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL25465130 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL25465866 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL826061 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL18537915 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL18697017 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL1070885 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683315-B2 | Prodrug of an HCV NS5B polymerase inhibitor and method of production and application thereof | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190054109-A1 | An antiviral composition and a method for application thereof | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2019-02-21 | — | — | US | disclosed |
| US-20180021360-A1 | Combination Therapy Regimen For Treatment Of Selected HCV Genotypes | Janssen Pharmaceuticals, Inc. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20180021360-A1 | Combination Therapy Regimen For Treatment Of Selected HCV Genotypes | Janssen Pharmaceuticals, Inc. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20180021361-A1 | COMBINATION DRUG TREATMENT FOR HEPATITIS C INFECTION | Janssen Pharmaceuticals, Inc. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20180021361-A1 | COMBINATION DRUG TREATMENT FOR HEPATITIS C INFECTION | Janssen Pharmaceuticals, Inc. (US) | 2018-01-25 | — | — | US | disclosed |
| WO-2018017989-A1 | COMBINATION THERAPY REGIMEN FOR TREATMENT OF SELECTED HCV GENOTYPES | Janssen Pharmaceuticals, Inc. (US) | 2018-01-25 | — | — | WO | disclosed |
| WO-2018017994-A1 | COMBINATION DRUG TREATMENT FOR HEPATITIS C INFECTION | Janssen Pharmaceuticals, Inc. (US) | 2018-01-25 | — | — | WO | disclosed |
| US-20170319572-A1 | COMBINATION DRUG TREATMENT FOR HEPATITIS C INFECTION | Janssen Pharmaceuticals, Inc. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170319572-A1 | COMBINATION DRUG TREATMENT FOR HEPATITIS C INFECTION | Janssen Pharmaceuticals, Inc. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20100041889-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | JANSSEN SCIENCES IRELAND UC (IE) | 2010-02-18 | — | — | US | disclosed |
| US-20100041889-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | JANSSEN SCIENCES IRELAND UC (IE) | 2010-02-18 | — | — | US | disclosed |
| US-20100029715-A1 | POLYMORPHIC FORMS OF A MACROCYCLIC INHIBITOR OF HCV | JANSSEN SCIENCES IRELAND UC (IE) | 2010-02-04 | — | — | US | disclosed |
| US-20100029715-A1 | POLYMORPHIC FORMS OF A MACROCYCLIC INHIBITOR OF HCV | JANSSEN SCIENCES IRELAND UC (IE) | 2010-02-04 | — | — | US | disclosed |
| US-20090281140-A1 | Macrocyclic inhibitors of hepatitis c virus | MEDIVIR AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090281140-A1 | Macrocyclic inhibitors of hepatitis c virus | MEDIVIR AB (SE) | 2009-11-12 | — | — | US | disclosed |
| WO-2008092955-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008092954-A2 | POLYMORPHIC FORMS OF A MACROCYCLIC INHIBITOR OF HCV | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008046860-A2 | BIOAVAILABLE COMBINATIONS FOR HCV TREATMENT | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-04-24 | — | — | WO | disclosed |
| WO-2007014926-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041889-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | PREP, SPINT2, PEPD | CTSS 31/4885CTSB 27/4885ADRB3 4662/4885 |
| US-20090281140-A1 | Macrocyclic inhibitors of hepatitis c virus | CYP2A7, CYP3A7, HCCS | CTSS 1949/4885CTSB 3370/4885ADRB3 2852/4885 |
| US-20190054109-A1 | An antiviral composition and a method for application thereof | RNASE1, ZC3HAV1, HCCS | CTSS 1026/4885CTSB 580/4885ADRB3 3756/4885 |
| US-20180021360-A1 | Combination Therapy Regimen For Treatment Of Selected HCV Genotypes | SLC10A1, HAVCR2, UGT1A3 | CTSS 1400/4885CTSB 1646/4885ADRB3 1240/4885 |
| US-20170319572-A1 | COMBINATION DRUG TREATMENT FOR HEPATITIS C INFECTION | HAVCR2, SLC10A1, CYP7A1 | CTSS 1342/4885CTSB 372/4885ADRB3 889/4885 |
| US-20180021361-A1 | COMBINATION DRUG TREATMENT FOR HEPATITIS C INFECTION | SLC10A1, HAVCR2, NR1H4 | CTSS 1124/4885CTSB 1087/4885ADRB3 610/4885 |
| US-20100029715-A1 | POLYMORPHIC FORMS OF A MACROCYCLIC INHIBITOR OF HCV | HLA-DRB1, CYP3A43, HAVCR2 | CTSS 723/4885CTSB 438/4885ADRB3 2756/4885 |
| US-10683315-B2 | Prodrug of an HCV NS5B polymerase inhibitor and method of production and application thereof | PNP, CYP7A1, UGT1A1 | CTSS 650/4885CTSB 318/4885ADRB3 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.